2 employees
Neurana Pharmaceuticals is currently developing a novel treatment for acute muscle spasms.
2013
$60M
from 4 investors over 4 rounds
Neurana Pharmaceuticals raised $60M on May 8, 2018
Investors: H.I.G. BioVentures, New Leaf Venture Partners, Sofinnova Ventures, Russia technology fund and Longitude Capital